Redeye embraces AroCell’s Q1’22 report, demonstrating good cost control and higher sales than expected (albeit still in small figures). We slightly up our Base Case following the report - our fair value range suggests a hefty upside from today’s share price levels, but we emphasize the market volatility and an overhang from guarantors’ commitments from the rights issue.